Skip to main content
Erschienen in: Die Kardiologie 6/2022

13.09.2022 | Hypercholesterinämie | Konsensuspapiere

Cholesterinsenkende Therapie bei älteren Patienten

Konsensuspapier der DGK und DGGG

verfasst von: Prof. Dr. Harald Rittger, David M. Leistner, Roland Hardt, Markus Dörr, Rainer Hambrecht, Rona Reibis, Sebastian Schellong, Stephan Henrik Schirmer, Alexander Wolf, Andreas Simm, Ursula Müller-Werdan, Ulf Landmesser

Erschienen in: Die Kardiologie | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

LDL(low density lipoprotein)-Cholesterin-senkende Therapien stellen einen etablierten Therapiebaustein in der kardiovaskulären Prävention dar. Für jüngere Patienten existiert eine breite Evidenz, die belegt, dass eine Statintherapie die Rate an kardiovaskulären Ereignissen bei Patienten mit bekannter koronarer Herzkrankheit (KHK) signifikant reduziert. Dies gilt auch für die primärpräventive Anwendung. Für ältere Patienten ist die bestehende Evidenz geringer, der Nutzen für ältere Patienten wird nach wie vor kontrovers diskutiert. Die bestehende Datenlage stützt sich bislang auf Subgruppenanalysen von randomisierten Studien, eine randomisierte Studie, die ausschließlich Patienten > 70 Jahren eingeschlossen hat, sowie Metaanalysen. Diese belegen jedoch, dass gerade ältere Patienten als Hochrisikogruppe von einer cholesterinsenkenden Therapie mindestens in gleichem Maße wie jüngere Patienten profitieren. Da geriatrische Syndrome wie Gebrechlichkeit, Komorbidität und Polypharmazie das Risiko für unerwünschte Ereignisse erhöhen, muss jedoch die Balance zwischen Risiko und Nutzen für jeden individuellen Patienten sorgfältig abgewogen werden.
Literatur
1.
Zurück zum Zitat Aboderin I, Kalache A, Ben-Shlomo Y et al (2002) Life course perspectives on coronary heart disease, stroke and diabetes: key issues and implications for policy and research. World Health Organization, Geneva Aboderin I, Kalache A, Ben-Shlomo Y et al (2002) Life course perspectives on coronary heart disease, stroke and diabetes: key issues and implications for policy and research. World Health Organization, Geneva
2.
Zurück zum Zitat Hawkins S, Wiswell R (2003) Rate and mechanism of maximal oxygen consumption decline with aging: implications for exercise training. Sports Med 33:877–888 CrossRefPubMed Hawkins S, Wiswell R (2003) Rate and mechanism of maximal oxygen consumption decline with aging: implications for exercise training. Sports Med 33:877–888 CrossRefPubMed
3.
Zurück zum Zitat Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76 CrossRefPubMed Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76 CrossRefPubMed
5.
Zurück zum Zitat Damiani I, Corsini A, Bellosta S (2020) Potential statin drug interactions in elderly patients: a review. Expert Opin Drug Metab Toxicol 16(12):1133–1145 CrossRefPubMed Damiani I, Corsini A, Bellosta S (2020) Potential statin drug interactions in elderly patients: a review. Expert Opin Drug Metab Toxicol 16(12):1133–1145 CrossRefPubMed
6.
Zurück zum Zitat Horodinschi RN, Stanescu AMA, Bratu OG et al (2019) Treatment with statins in elderly patients. Medicina (Kaunas) 55:721 CrossRefPubMed Horodinschi RN, Stanescu AMA, Bratu OG et al (2019) Treatment with statins in elderly patients. Medicina (Kaunas) 55:721 CrossRefPubMed
7.
Zurück zum Zitat Ruscica M, Macchi C, Pavanello C et al (2018) Appropriateness of statin prescription in the elderly. Eur J Intern Med 50:33–40 CrossRefPubMed Ruscica M, Macchi C, Pavanello C et al (2018) Appropriateness of statin prescription in the elderly. Eur J Intern Med 50:33–40 CrossRefPubMed
8.
Zurück zum Zitat Fulcher J, O’Connel R, Voysey M et al (2015) Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174.000 participants in 27 randomised trials. Lancet 385:1397–1405 CrossRefPubMed Fulcher J, O’Connel R, Voysey M et al (2015) Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174.000 participants in 27 randomised trials. Lancet 385:1397–1405 CrossRefPubMed
9.
Zurück zum Zitat Ford I, Murray H, McCowan C, Packard C (2016) Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy. 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation 133:1073–1080 CrossRefPubMedPubMedCentral Ford I, Murray H, McCowan C, Packard C (2016) Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy. 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation 133:1073–1080 CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Lewis SJ, Moye LA, Sacks FM et al (1998) Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 129:681–689 CrossRefPubMed Lewis SJ, Moye LA, Sacks FM et al (1998) Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 129:681–689 CrossRefPubMed
11.
Zurück zum Zitat Hunt D, Young P, Simes J et al (2001) Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 134:931–940 CrossRefPubMed Hunt D, Young P, Simes J et al (2001) Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 134:931–940 CrossRefPubMed
12.
Zurück zum Zitat Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER). Lancet 360:1623–1630 CrossRefPubMed Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER). Lancet 360:1623–1630 CrossRefPubMed
13.
Zurück zum Zitat Gencer B, Nicholas AM, Im KA et al (2020) Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomized controlled trials. Lancet 396:1637–1643 CrossRefPubMedPubMedCentral Gencer B, Nicholas AM, Im KA et al (2020) Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomized controlled trials. Lancet 396:1637–1643 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Javed U, Deedwania PC, Bhatt DL et al (2011) Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65.396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J 161:418–424 CrossRefPubMed Javed U, Deedwania PC, Bhatt DL et al (2011) Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65.396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J 161:418–424 CrossRefPubMed
16.
Zurück zum Zitat Cholesterol Treatment Trialists’ Collaboration. (2019) Efficacy and safety of statin therapy in older people: a metaananlysis of individual participant data from 28 randmoised controlled trials. Lancet 393:407–415 CrossRef Cholesterol Treatment Trialists’ Collaboration. (2019) Efficacy and safety of statin therapy in older people: a metaananlysis of individual participant data from 28 randmoised controlled trials. Lancet 393:407–415 CrossRef
17.
Zurück zum Zitat Savarese G, Gotto AM Jr (2013) Paolillo S et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol 62:2090–2099 CrossRefPubMed Savarese G, Gotto AM Jr (2013) Paolillo S et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol 62:2090–2099 CrossRefPubMed
18.
Zurück zum Zitat Kostis JB, Giakoumis M, Zinonos S et al (2020) Meta-analysis of usefulness of treatment of hypercholesterolemia with statins for primary prevention in patients older than 75 years. Am J Cardiol 125(8):1154–1157 CrossRefPubMed Kostis JB, Giakoumis M, Zinonos S et al (2020) Meta-analysis of usefulness of treatment of hypercholesterolemia with statins for primary prevention in patients older than 75 years. Am J Cardiol 125(8):1154–1157 CrossRefPubMed
19.
Zurück zum Zitat Giral P, Neumann A, Weill A et al (2019) Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J 40:3516–3525 CrossRefPubMedPubMedCentral Giral P, Neumann A, Weill A et al (2019) Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J 40:3516–3525 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bach RG, Cannon CP, Giugliano RP et al (2019) Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older. A secondary analysis of a randomized clinical trial. JAMA Cardiol 4:846–854 CrossRefPubMedPubMedCentral Bach RG, Cannon CP, Giugliano RP et al (2019) Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older. A secondary analysis of a randomized clinical trial. JAMA Cardiol 4:846–854 CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Orkaby AR, Driver JA, Ho YL et al (2020) Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA 324:68–78 CrossRefPubMedPubMedCentral Orkaby AR, Driver JA, Ho YL et al (2020) Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA 324:68–78 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Mortensen MB, Nordestgaard BG (2020) Elevated cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet 396:1644–1652 CrossRefPubMed Mortensen MB, Nordestgaard BG (2020) Elevated cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet 396:1644–1652 CrossRefPubMed
23.
Zurück zum Zitat Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet 380:572–580 CrossRefPubMedPubMedCentral Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet 380:572–580 CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Mach F, Baigent C, Catapano A et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188 CrossRefPubMed Mach F, Baigent C, Catapano A et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188 CrossRefPubMed
25.
Zurück zum Zitat Visseren FL, Mach F, Smulders YM et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42:3227–3337 CrossRefPubMed Visseren FL, Mach F, Smulders YM et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42:3227–3337 CrossRefPubMed
26.
Zurück zum Zitat Falk E, Mortensen MB (2016) Statin therapy on the basis of HOPE. J Am Coll Cardiol 68:2903–2909 CrossRefPubMed Falk E, Mortensen MB (2016) Statin therapy on the basis of HOPE. J Am Coll Cardiol 68:2903–2909 CrossRefPubMed
27.
Zurück zum Zitat Mortensen M, Erling F (2018) Primary prevention with statins in the elderly. J Am Coll Cardiol 71:85–94 CrossRefPubMed Mortensen M, Erling F (2018) Primary prevention with statins in the elderly. J Am Coll Cardiol 71:85–94 CrossRefPubMed
28.
Zurück zum Zitat Ganga HV, Slim HB, Thompson PD (2014) A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168(1):6–15 CrossRefPubMed Ganga HV, Slim HB, Thompson PD (2014) A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168(1):6–15 CrossRefPubMed
29.
Zurück zum Zitat Collins R, Reith C, Emberson J et al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388:2532–2561 CrossRefPubMed Collins R, Reith C, Emberson J et al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388:2532–2561 CrossRefPubMed
Metadaten
Titel
Cholesterinsenkende Therapie bei älteren Patienten
Konsensuspapier der DGK und DGGG
verfasst von
Prof. Dr. Harald Rittger
David M. Leistner
Roland Hardt
Markus Dörr
Rainer Hambrecht
Rona Reibis
Sebastian Schellong
Stephan Henrik Schirmer
Alexander Wolf
Andreas Simm
Ursula Müller-Werdan
Ulf Landmesser
Publikationsdatum
13.09.2022
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 6/2022
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-022-00575-z

Weitere Artikel der Ausgabe 6/2022

Die Kardiologie 6/2022 Zur Ausgabe

Update Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.